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1078–5Objectives. To investigate the effects of exercise training on levels of circulating biomarkers associated with the progres-
sion of atherosclerosis and risk of cardiovascular events in patients with intermittent claudication.
Methods. Circulating levels of soluble adhesion molecules (sVCAM-1, sICAM-1, sE-selectin), high sensitivity C-reactive
protein (hs-CRP) and stress proteins (Hsp60 and Hsp70) in patients randomised to a 24-week programme of arm- or leg-
cranking exercise were compared with those in usual care controls.
Results. Arm and leg exercise similarly improved lower-limb aerobic exercise capacity (20% vs 19%, respectively;
P< 0.001) and maximum walking distance (30% vs 35%, respectively; P< 0.001). Improvements in training limb-specific
peak oxygen consumption were attenuated for patients in the highest vs lowest quartile for circulating sVCAM-1 levels at
baseline (3% vs 25% respectively, P< 0.001). Although circulating hs-CRP levels tended to be lower in the arm-cranking
group (1.55 [95% CI: 1.06 to 2.26] mg l1), exercise training had no effect on circulating levels of soluble adhesion
molecules or stress proteins.
Conclusions. These findings suggest that high levels of circulating sVCAM-1 are associated with an attenuated exercise
training response and that arm-cranking exercise may provide an effective stimulus for evoking systemic anti-inflamma-
tory adaptations in patients with intermittent claudication.
 2007 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
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The incidence of mortality from cardiovascular events
in patients with intermittent claudication is high.1,2
Patients with intermittent claudication are also at an
increased risk of non-fatal coronary1 and cerebrovascu-
lar3 events. Although recent evidence has shown that
programmes of arm- and leg-cranking exercise can
improve pain-free and maximum walking distance innical trial registration information: ISRCTN76180797. URL:
www.controlled-trials.com/isrctn/trial/SAXTON/0/76180797.
sponding author. Dr. J. M. Saxton, PhD, Centre for Sport and
se Science, Sheffield Hallam University, Collegiate Crescent
s, Sheffield S10 2BP, UK.
address: j.m.saxton@shu.ac.uk
884/000607+ 07 $34.00/0  2007 European Society for Vasculapatients with intermittent claudication,4 the impact of
these exercise training modalities on blood markers
that are associated with atherosclerosis and the risk
of future cardiovascular events is unknown.
Evidence suggests that adhesion molecules ex-
pressed on the surface of leukocytes and vascular
endothelial cells might have an integral role in athero-
genesis. Circulating levels of soluble vascular cell ad-
hesion molecule-1 (sVCAM-1) are highly correlated
with the extent of atherosclerosis5 and independently
predict maximum intima-media thickness at the ca-
rotid bifurcation in patients with peripheral arterial
disease.6 Elevated levels of soluble intercellular adhe-
sion molecule-1 (sICAM-1) have also been associated
with the progression of atherosclerosis in claudicants,7
and high levels of soluble E-selectin (sE-selectin) arer Surgery. Published by Elsevier Ltd. All rights reserved.
608 J. M. Saxton et al.predictive of restenosis after percutaneous translumi-
nal angioplasty in this patient group.8
The inflammatory events that underpin the devel-
opment and progression of atherosclerosis are also re-
flected by elevated circulating levels of high sensitivity
C-reactive protein (hs-CRP).9 Circulating hs-CRP levels
are associated with the clinical severity and progres-
sion of atherosclerosis in patients with peripheral arte-
rial disease.10,11 Accumulating evidence suggests that
heat shock (stress) proteins, which function as intracel-
lular signalling molecules and can mediate a range of
inflammatory and anti-inflammatory effects, could
also be involved in atherogenesis.12,13
Given the elevated risk of cardiovascular mortality
in patients with intermittent claudication, this study
investigated the effects of a six-month programme of
arm- and leg-cranking exercise training on blood
markers of atherosclerosis and future cardiovascular
risk.Materials and Methods
Patients
A total of 104 patients (median age 69 yr, range 50e
85 yr) with stable intermittent claudication were re-
cruited from the Sheffield Vascular Institute at the
Northern General Hospital, Sheffield, U.K. The clinical
diagnosis of peripheral arterial disease was established
using the patient’s history and physical examination,
and was confirmed by the Doppler assessment of
ankle-brachial pressure index (ABPI). Patients with an-
eurysmal disease and those experiencing symptoms of
intermittent claudication for <12 months or reporting
a significant change in walking ability within this
time period (considered to have unstable disease)
were excluded. Ethical approval was obtained from
the North Sheffield Local Research Ethics Committee
and all patients provided informed consent before
entering the study.Patient randomisation
Following the assessment of baseline outcome mea-
sures, patients were randomised into one of three
groups: (i) arm-cranking exercise, (ii) leg-cranking
exercise, or (iii) usual care control group. The usual
care group were encouraged to engage in a physically
active lifestyle, but were not offered any supervised
exercise sessions. Walking performance data and
other physiological outcomes for the cohort of 104
patients have been reported previously.4 Herein, cir-
culating biomarker data for 92 of the patients, fromEur J Vasc Endovasc Surg Vol 35, May 2008whom venous blood samples were collected at base-
line and 24-weeks (arm-cranking exercise: N¼ 30;
leg-cranking exercise: N¼ 32; usual care control
group: N¼ 30) are presented. Demographic data for
the patient cohort are provided in Table 1.
Supervised exercise training
Supervised arm- or leg-cranking exercise training was
performed at equivalent relative exercise intensities
(85e90% of the limb-specific peak oxygen uptake)
twice a week for a total of 24 weeks, as previously de-
scribed.4 Briefly, patients exercised in cycles of two
minutes exercise at a crank rate of 50 revolutions
per minute, followed by two minutes rest for a total
exercise time of 20 minutes in a 40-minute session. In-
cremental arm- and leg-cranking tests to maximum
exercise tolerance were performed during weeks 6,
12 and 18 of the intervention. This allowed the respec-
tive upper- and lower-limb exercise intensities to be
adjusted on an individual basis (where appropriate)
and ensured the progression of the exercise stimulus.
Peak upper- and lower-limb oxygen consumption
were recorded during these assessments as described
previously.4 Compliance to the arm- and leg-cranking
exercise training was excellent (w99%). Although pa-
tients in the control group were given lifestyle advice,
including encouragement to undertake regular exer-
cise, they did not undertake any supervised exercise.
Outcome measures
Outcomes were assessed at baseline and after the
intervention period at 24 weeks. All blood samples
were taken at the same time of day and were collected
into Vacutainer tubes (Beckton Dickinson Ltd, Oxford,
UK) that contained no anticoagulant for serum
analysis. Serum samples were stored at 80 C until
analysis.
Serum levels of soluble adhesion molecules,
inflammatory markers and stress proteins
Serum levels of the soluble adhesion molecules
(sICAM-1, sVCAM-1, sE-selectin) were measured
according to the manufacturer’s recommended proto-
cols using commercially-available Eli-Pair immunoas-
say kits (Diaclone Research via Immunodiagnostic
Systems Ltd, Boldon. U.K.). Levels of hs-CRP were
measured using the Dade Behring nephelometric ap-
proach in the Immunology and Protein Reference
Unit at Sheffield Teaching Hospitals NHS Foundation
Trust (Northern General Hospital, Sheffield). Levels of
Table 1. Demographics of the three study groups
Variable Leg training (N¼ 32) Arm training (N¼ 30) Control (N¼ 30) P
Median age (range) 68 (50e85) 66 (54e82) 72 (56e84) 0.09a
Body weight, kg 74.9 2.2 81.6 1.7 78.2 3.4 0.21a
Height, m 1.68 0.01 1.68 0.01 1.67 0.01 0.84a
Body mass index 26.4 0.6 29.1 0.7 27.8 1.0 0.06a
Sex
Male, % 78 77 73 0.20b
Female, % 22 23 27
Resting ABPI 0.64 0.03 0.65 0.03 0.69 0.03 0.57a
Duration of claudication, months 58 9 46 7 56 7 0.56a
Angina, % 16 20 23 0.59b
Previous myocardial infarction, % 3 9 7 0.55b
Previous stroke, % 22 17 17 0.83b
Diabetes mellitus, % 6 17 27 0.09b
Smoking status
Current 38 23 36 0.41b
Previous 53 74 57 0.23b
Never smoked 9 3 7 0.63b
Medication
Beta-blockers, % 22 20 33 0.88b
ACE-inhibitors, % 16 17 13 0.93b
Calcium blockers, % 22 33 30 0.56b
Diuretics, % 37 27 27 0.56b
Nitrates, % 12 7 10 0.74b
Digoxin, % 9 0 7 0.25b
Warfarin, % 9 0 0 0.06b
Statins, % 78 73 60 0.27b
Acetyl-salicylic acid, % 81 83 87 0.84b
ABPI data are presented for the most symptomatic limb. Patients with diabetes mellitus were taking oral hypoglycemics or insulin. Unless
otherwise stated, values are means SE.
a ANOVA.
b Chi Square test.
609Effects of Exercise Training on Biomarkers in ClaudicantsHsp60 and Hsp70 were determined by enzyme im-
munoassays, as described previously.14,15 All assess-
ments were performed blindly by members of the
research team not involved with the supervised exer-
cise training or the assessment of other outcomes.Walking performance
Walking performance was assessed using an incre-
mental shuttle-walk test as described previously.4
Briefly, patients walked back and forth between two
cones placed 10 metres apart on a flat floor. Walking
speed was controlled by bleeps recorded onto an
audio-tape. The distance walked before the onset of
claudication pain (claudication distance, CD) and
the maximum walking distance (MWD) which was
achieved before the test was terminated due to intol-
erable claudication pain were calculated.Data analysis
The sample size calculation was based on relative risk
data for circulating sVCAM-1 reported by Jager et al.16
and the change in this outcome which was evoked by12 weeks of leg-cranking exercise in patients with
chronic heart failure.17 Dependent variables were first
tested for normal distribution using the Kolmogorove
Smirnov goodness of fit test. As all blood variables
were positively skewed, they were normalised by log-
arithmic transformation before further analysis. These
data are expressed as geometric mean values, with
95% confidence intervals in parentheses (antilog of
the log-transformed mean and 95% confidence inter-
vals). Normally distributed data are reported as
means SE. Changes between the groups from base-
line to 24 weeks were compared using analysis of
covariance, with baseline measures being used as
the covariate to improve sensitivity of the analysis.
Post hoc tests were used, where appropriate, to high-
light mean differences. As the incidence of cardiovas-
cular events during 24 months of follow-up was
reported to be lower for patients with hs-CRP levels
of <1.72 mg l1,10 the Chi Square test was used to test
for differences in the proportion of patients below
this cut-point between groups at baseline and 24
weeks. Bivariate relationships among levels of circulat-
ing inflammatory mediators, peak oxygen uptake and
walking performance were assessed using the Spear-
man’s rho correlation coefficient for non-parametricEur J Vasc Endovasc Surg Vol 35, May 2008
610 J. M. Saxton et al.data. All data were analysed using the SPSS statistical
package (SPSS UK Ltd, Woking, U.K.), and the statisti-
cal significance was set at P< 0.05.Results
The average improvements in walking performance
over the 24-week study period were comparable in
exercising patients (56% vs 65% and 30% vs 35% for
CD and MWD in the upper- and lower-limb exercise
groups, respectively). Corresponding improvements
in lower-limb peak oxygen uptake for the upper-
and lower-limb exercise training groups were 20%
and 19%, respectively. No change in walking perfor-
mance or peak oxygen uptake was apparent in the
control group. The proportion of patients taking med-
ications for comorbid conditions was similar in the
different groups (Table 1) and was consistent for the
duration of the study.
Exercise training had no effect on circulating levels
of soluble adhesion molecules or stress proteins (Table 2).
However, low but significant negative correlations
were observed, between baseline walking perfor-
mance and circulating levels of sVCAM-1 and sE-
selectin (0.27 to 0.32; P 0.05), indicating that
higher circulating levels of these adhesion moleculesTable 2. Serum levels of soluble adhesion molecules, hs-CRP and st
Baseline
sE-selectin (ngml1)
Leg cranking group 114 (96e136)
Arm-cranking group 119 (97e148)
Control group 106 (78e145)
sICAM-1 (ngml1)
Leg cranking group 1028 (896e1178)
Arm-cranking group 1017 (893e1158)
Control group 991 (838e1171)
sVCAM-1 (ngml1)
Leg cranking group 1327 (1160e1519)
Arm-cranking group 1542 (1365e1742)
Control group 1453 (1263e1671)
hs-CRP (mg l1)
Leg cranking group 3.16 (2.14e4.72)
Arm-cranking group 2.53 (1.76e3.63)
Control group 3.39 (2.32e4.95)
Hsp60 (mgml1)
Leg cranking group 0.193 (0.091e0.410)
Arm-cranking group 0.299 (0.147e0.609)
Control group 0.189 (0.088e0.301)
Hsp70 (mgml1)
Leg cranking group 0.085 (0.045e0.159)
Arm-cranking group 0.097 (0.054e0.175)
Control group 0.098 (0.058e0.163)
Data are presented as geometric mean values with 95% confidence int
the ANCOVA analyses.
Eur J Vasc Endovasc Surg Vol 35, May 2008are associated with a greater impairment of physical
function. In addition, baseline levels of sVCAM-1
were moderately (and negatively) correlated (r¼0.40;
P¼ 0.001) with the subsequent improvement in arm-
or leg-cranking peak oxygen consumption in patients
randomised to arm- and leg-crank training respec-
tively (Table 3; Fig. 1A).
Further analysis revealed that patients in the
highest quartile for circulating sVCAM-1 at baseline
(range 1718e3304 ngml1) exhibited a poorer exercise
training response in terms of the change in limb-
specific peak oxygen consumption, than patients in
the lowest quartile for circulating sVCAM-1 at base-
line (range 753e1050 ngml1) (Fig. 1B). The mean
(SE) changes in peak oxygen consumption for
patients in the highest and lowest quartiles for circu-
lating sVCAM-1 at baseline were 0.02 0.05 and
0.26 0.04 l min1 respectively, and this difference
was statistically significant (P< 0.001). Expressed as
a percentage, these changes represent respective im-
provements of 3 5% and 25 4% in peak oxygen
consumption.
The magnitude of the reduction in circulating
hs-CRP relative to the control group was 1.55 (1.06e
2.26) mg l1 in the arm-cranking group compared to
1.27 (0.88e1.83) mg l1 in the leg-cranking group
(Fig. 2). In addition, the proportion of patients in theress proteins
24 weeks P
104 (87e126) 0.26
118 (97e144)
103 (74e143)
997 (852e1167) 0.68
1019 (894e1161)
943 (827e1076)
1310 (1155e1486) 0.72
1422 (1264e1600)
1344 (1192e1515)
2.73 (1.86e4.00) 0.07
1.88 (1.28e2.74)
3.63 (2.4e5.48)
0.189 (0.087e0.109) 0.47
0.338 (0.171e0.669)
0.178 (0.102e0.311)
0.084 (0.046e0.154) 0.44
0.115 (0.067e0.158)
0.098 (0.061e0.158)
ervals in parentheses. P values in the table relate to main effects for
Table 3. Spearman correlation coefficients for selected variables
Variable sVCAM-1 sICAM-1 sE-Selectin hs-CRP
Baseline CD 0.27* 0.07 0.23* 0.14
Baseline MWD 0.32** 0.07 0.21* 0.16
DCD 0.10 0.25* 0.07 0.16
DMWD 0.17 0.07 0.04 0.05
D _V O2 0.40** 0.23 0.19 0.14
DCD, DMWD and D _V O2 indicate change in claudication distance,
maximum walking distance and limb-specific peak oxygen con-
sumption from the baseline level at the 24-week post-intervention
time-point (*P< 0.05; **P< 0.01).
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Fig. 2. The magnitude of the reduction in circulating hs-CRP
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Fig. 1. A: Scatterplot showing the correlation between the
change in peak oxygen consumption and serum sVCAM-1
concentration; B: Change in training limb-specific peak oxy-
gen consumption in patients exhibiting sVCAM-1 concen-
trations in the highest and lowest quartiles at baseline.
**P< 0.001 between the highest and lowest quartile
sVCAM-1 concentrations. Data are means SE.
in patients undergoing exercise patients relative to usual
care following the 24-week intervention. Data are geometric
mean differences, with error bars representing 95% confi-
dence intervals. j P¼ 0.07 between the arm-cranking and
control group.Discussion
This study determined whether arm- and leg-cranking
exercise training influenced the levels of bloodmarkers
that have been associated with the extent of atheroscle-
rosis and the risk of future cardiovascular events in
patients with intermittent claudication. As reported
previously, these two exercise regimens evoked a simi-
lar improvement in walking performance and lower-
limb peak oxygen consumption.4 Smoking behaviour
was reported to be unchanged during the exercise in-
tervention and is therefore unlikely to have affected
the change in walking distances.
Although no reduction in circulating soluble adhe-
sion molecules in the patients undergoing exercise
training was observed, sVCAM-1 levels at baseline
were moderately and negatively associated with the
change in training limb-specific peak oxygen con-
sumption in these patients. In addition, exercising pa-
tients in the highest quartile for circulating sVCAM-1
at baseline exhibited a significantly poorer improve-
ment in training limb-specific peak oxygen consump-
tion than patients in the lowest sVCAM-1 quartile (3%
vs 25% improvement, respectively). Interestingly, low
but significant negative correlations between walking
performance and baseline levels of sVCAM-1 and sE-
selectin were also observed in our patient cohort.
Although we have no direct measurements of athero-
sclerotic burden, circulating sVCAM-1 levels are
associated with the extent of atherosclerosis in pa-
tients with intermittent claudication.5,6 Hence, we
can speculate that patients with increased disease
severity at baseline had a lower functional capacityEur J Vasc Endovasc Surg Vol 35, May 2008
612 J. M. Saxton et al.and responded less well to the exercise training than
patients with less severe disease.
There was a strong trend for a decrease in circulat-
ing hs-CRP levels following arm-cranking exercise
training, however this trend did not reach statistical
significance due to a reduced statistical power for
this outcome (the sample size calculation was based
on a clinically important change in circulating
sVCAM-1 levels, which was not observed). Neverthe-
less, the magnitude of the reduction in hs-CRP could
represent a clinically important change. Vainas et al.
(2005)10 have shown that the incidence of cardiovascu-
lar events during 24-months of follow-up in patients
with higher circulating levels of hs-CRP at baseline
(>1.72 mg l1) was greater than that in patients with
lower levels of circulating hs-CRP (<1.72 mg l1).10 In
our cohort, the proportion of arm-cranking patients
with hs-CRP levels below 1.72 mg l1 was increased
to 50% at the 24-week (post-intervention) time-point.
This was significantly greater than the proportion of
patients in the control group that were below this
threshold level (23%). Although drugs such as statins,
aspirin, beta-blockers and ACE inhibitors can have
a lowering-effect on circulating CRP levels,18 they are
unlikely to have influenced circulating hs-CRP levels
in the present study. Patients did not change their
medication during the intervention period and the
proportions of patients taking a given medication
were similar between the groups.
It is unclear why a reduction in hs-CRP levels was
apparent in the absence of any changes in soluble
adhesion molecules which are likely to be shed from
atherosclerotic plaques.19 Although CRP has also
been detected in femoral plaques,10,20 it is primarily
secreted by hepatocytes in response to pro-inflamma-
tory cytokines and is more likely to be indicative of
systemic inflammation. Hence, it might be that
changes in hs-CRP levels reflect a generalised systemic
anti-inflammatory effect of chronic upper-limb exer-
cise training in our patient cohort, rather than changes
in the underlying level of atherosclerosis. Reductions
in hs-CRP and proinflammatory cytokines following
programmes of exercise training in patients with cor-
onary heart disease21 and those at high risk of devel-
oping the disease22 have previously been reported. In
claudicants, arm exercise could be a more effective
stimulus for evoking systematic anti-inflammatory
adaptations than leg exercise, due to the higher rela-
tive upper-limb exercise intensities that can be sus-
tained in a significant proportion of patients.23 A
reduction in inflammatory markers after programmes
of exercise training can have a positive impact on
endothelial function24 and this could have under-
pinned the improvement in walking performance inEur J Vasc Endovasc Surg Vol 35, May 2008the upper-limb exercise group. While the concept of
a systemic exercise-induced anti-inflammatory effect
is compelling, this must be confirmed with further
investigations.
Exercise training had no effect on resting levels of
stress proteins in our patient cohort. Positive associa-
tions between Hsp60 and atherosclerotic disease have
been reported,25,26 whereas high circulating levels of
Hsp70 are associated with protection against the fu-
ture development of atherosclerosis in subjects with
established hypertension.27,28 No previous studies
have investigated the effects of an aerobic exercise in-
tervention on circulating stress protein concentrations
in this patient population and our findings indicate
that improvements in cardiopulmonary function and
clinical symptoms are independent of changes in cir-
culating levels of Hsp60 or Hsp70.
The attenuated exercise training response in pa-
tients with the highest circulating sVCAM-1 levels at
baseline raises the possibility that circulating levels
of this marker could be useful for identifying patients
who are less likely to benefit from exercise training. In
addition, the strong trend for a decrease in circulating
hs-CRP in the upper-limb exercise group suggests that
such alternative forms of exercise rehabilitation might
have a positive impact on the cardiovascular risk
profiles of patients with intermittent claudication.
However, further studies with larger patient cohorts
and longer-term follow-up measures are needed to
establish the true clinical significance of exercise-
induced changes in hs-CRP.
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